Phase II study of rapid-scheduled etoposide in paediatric soft tissue sarcomas.
Eur J Cancer
; 31A(5): 782-4, 1995.
Article
em En
| MEDLINE
| ID: mdl-7640053
ABSTRACT
Twenty three patients with paediatric soft tissue sarcomas who had relapsed or refractory disease were treated with a rapid schedule of intravenous etoposide (100 mg/m2 daily on three consecutive days, weekly over 3 weeks). The regimen was well tolerated with predictable myelotoxicity. In 19 patients with rhabdomyosarcoma, there was a response rate of 42%. This appears to be better than previously reported with conventional three weekly schedules. These data indicate that for rhabdomyosarcoma, as for some other tumours, a divided dose regimen may be the optimal schedule and is worthy of further evaluation.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Sarcoma
/
Etoposídeo
Limite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Ano de publicação:
1995
Tipo de documento:
Article